Advertisement

Picture EBD Group World of Partnering Opportunities 650x100px
Organisation › Details

Bit Bio Ltd. (bit.bio)

bit.bio is a synthetic biology company focused on human cells that is advancing medicine (UN SDG9) and enabling curative treatments (UN SDG3). The company does this by industrializing the manufacture of human cells and making them more accessible. The company was spun out of the University of Cambridge in 2016 and has since raised approximately $200m from investors such as Arch Ventures, Foresite Capital, Milky Way, Charles River Laboratories, National Resilience, Tencent, Verition Fund and Puhua Capital. bit.bio’s opti-ox™ precision cell programming and manufacturing technology enables conversion of induced pluripotent stem cells (iPSCs) into any desired human cell type in a single step. This can be achieved within days and at industrial scale, while maintaining exceptional purity and unparalleled consistency. Our discovery platform extends this approach to any desired cell type by identifying the transcription factor combinations that define cell states (including identity, cell subtype identity, maturity) using high throughput screens and advanced data analysis. We believe that opti-ox can revolutionize regenerative medicine similarly to how CRISPR is unlocking gene therapy. bit.bio's cell therapy pipeline is focused on serious diseases that currently lack effective treatments. Our preclinical research areas include liver, immunology and metabolic disease, and we have a collaboration with BlueRock Therapeutics (Bayer AG) to create therapeutics for autoimmune and inflammatory disorders. In addition, our extensive ioCells™ research cell product portfolio, which includes wild type and disease model cells, is opening up new possibilities for studying human biology and developing new medicines in both research and high throughput and high content drug discovery. *

 

Period Start 2019-10-15 renamed
  Predecessor Elpis BioMed Ltd.
Products Industry opti-ox™ cell reprogramming platform (optimised, inducible over-expression)
  Industry 2 synthetic biotechnology
Persons Person Kotter, Mark (Elpis BioMed (bit.bio today) 2017– CEO + Founder)
  Person 2 Milner, Jonathan (Abcam 201409 Deputy Chairman + largest shareholder before CEO + Co-founder)
     
Region Region Cambridge, Cambridgeshire
  Country United Kingdom (GB)
  Street Discovery Drive
Cambridge Biomedical Campus
  City CB2 0AX Cambridge, Cambridgeshire
    Address record changed: 2024-01-05
     
Basic data Employees D: 101 to 500 (2021-11-05)
     
    * Document for »About Section«: Synthego Corporation. (8/24/23). "Press Release: Synthego and bit.bio Expand Strategic Partnership to Build a Platform for the Development of Safer and More Efficient Genetic Engineering of Human Cells for Cell Therapies". Redwood City, CA & Cambridge.
     
   
Record changed: 2024-06-07

Advertisement

Picture Berlin Partner Voices Martin Rahmel TU Berlin GreenChem 650x200px

More documents for Bit Bio Ltd. (bit.bio)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Voices Martin Rahmel TU Berlin GreenChem 650x300px




» top